Tilly's, Inc. TLYS 深 滬
等待開盤 08-23 09:30:00 美东时间
1.805
+0.275
+17.97%
華盛通- 最 高1.8302
- 今 開1.59
- 成交量 31.03万股
- 最 低 1.5624
- 昨 收 1.53
- 總市值 5442.42万
- 52周最高 5.35
- 市盈率 靜 --
- 換手率 1.03%
- 52周最低 0.571
- 委 比 70.94%
- 總股本 3015.19万
- 歷史最高 21.46
- 量 比 3.71
- 振 幅 17.50%
- 歷史最低 -0.21
- 每 手 1
- 風險率 1.23%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Tilly's shares are trading higher after the company announced a new appointee for the president, CEO, and director roles.
Tilly's shares are trading higher after the company announced a new appointee f...
07-29 02:03
Tilly’s Announces New CEO Appointment
An update from Tilly’s ( ($TLYS) ) is now available. On July 25, 2025, Tillys a...
07-28 20:49
12 Consumer Discretionary Stocks Moving In Friday's Intraday Session
Gainers Sonder Holdings (NASDAQ:SOND) shares moved upwards by 23.4% to $1.98 d...
06-28 01:05
Tilly’s Stockholders Approve Key Proposals at Annual Meeting
An announcement from Tilly’s ( ($TLYS) ) is now available. At Tilly’s 2025 annu...
06-12 05:52
美股大行评级 | 潜在涨幅925.64%！Aemetis获Ascendiant Capital升目标价至20美元，维持"买入"评级
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1138028221594226688.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• Ascendiant Capital：维持Aemetis(AMTX)"买入"评级，目标价从19美元升至20美元</p> <p>• Ascendiant Capital：维持Lucid Diagnostics(LUCD)"买
06-07 08:37
美股大行评级 | 潜在涨幅6326.33%！Ascendiant Capital上调Plus Therapeutics目标价至20.5美元，维持"买入"评级
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1137665801621229569.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• Ascendiant Capital：维持Plus Therapeutics(PSTV)"买入"评级，目标价从20美元升至20.5美元</p> <p>• Ascendiant Capital：维持RenovoRx(RNXT
06-06 09:45
电话会总结 ｜ Tilly's Q1 2025 业绩电话会核心要点
<span> <meta content="no-referrer" name="referrer"></span><span style="color:#999999;">编者按：聚焦公司高管观点与展望，深挖业绩背后的信息，助力投资者把握先机。</span><blockquote> <p><span style="color:#fa1432;"><strong>业绩回顾</strong></span></p></blockquote><p>• **财务业绩**： - Tilly's在2025财年第一季度实现总营收1.076亿美元，同比下降7.1%。 - 实体店销售额下降7.4%，电子商务销售额下降5.8%。 - GAAP净亏损为2220万美元，每股亏损0.74美元，而去年同期为净亏损1960万美元，每股亏损0.65美元。 - 毛利率（GAAP）为19.8%，低于去年同期的21%。 - 运营现金流表现稳健，期末总流动性为9260万美元，包括3720万美元的现金及有价证券，以及
06-05 12:02
Tilly's shares are trading higher after the company issued Q2 sales guidance above estimates.
Tilly's shares are trading higher after the company issued Q2 sales guidance ab...
06-05 04:14
Tilly's Sees Q2 GAAP EPS $(0.09)-$(0.07) vs $(0.06) Est; Sees Sales $150.000M-$158.000M vs $147.22M Est
Tilly's (NYSE:TLYS) is looking for Q2 GAAP EPS of $(0.09)-$(0.07) vs $(0.06) analyst estimate. sees sales of $150.000 million-$158.000 million vs $147.22 million analyst estimate.
06-05 04:09
Tilly's Q1 EPS $(0.74) Misses $(0.66) Estimate, Sales $107.60M Miss $108.20M Estimate
Tilly's (NYSE:TLYS) reported quarterly losses of $(0.74) per share which missed the analyst consensus estimate of $(0.66) by 12.12 percent. This is a 54.17 percent decrease over losses of $(0.48) per share from the same
06-05 04:08
